| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | RNA-Based Therapies | Nervous System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | RNA-Based Therapies | Nervous System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | RNA-Based Therapies | Nervous System |
Recent Updates
Recently added Catalysts
Ionis Pharmaceuticals, Inc.$58.25
-6.07 (-9.44%)
B 74Pipeline Score Undervalued Pharma · Commercial
Market Cap
12.49 B
EPS
-2.00
P/E Ratio
-
Value Trade
95.96 M
SEC Financials
Q1 2026Dilution Risk
Revenue
246.09 M
Operating CF
-792.82 M
Total Assets
3.45 B
Total Liabilities
2.96 B
Equity
491.41 M
D/E Ratio
12,345
-0.43 %
Week
0.45 %
1 Month
-8.8 %
3 Month
3.51 %
6 Month
105.77 %
5 Year
655.6 %
All Time
Cash Data
Cash Position
1.92 B
Monthly Burn
264.27 M
Runway
5.1 mo
Burn Trend
SEC Filing
Apr 29, 2026
Overview
Volume
11.61 M
52 Week Range
32 - 86.74
% held by Insiders
1.95 %
% held by Institutions
104.4 %
Enterprise Value
13.12 B
Total Shares
165.26 M
Short %
10.7 %
Float Shares
162.78 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ionis Pharmaceuticals, Inc.
368Total events
7Upcoming
169Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 7
Event history 361
Jul 9, 2026
▼Primary Endpoint MissedEplontersenApprovedClinical Data
CARDIO-TTRansform Phase 3 trial of eplontersen did not meet primary efficacy endpoint
transthyretin-mediated amyloid cardiomyopathysource ↗
Jul 6, 2026
▲Enrollment CompleteobudanersenTrial
Completed enrollment in pivotal cohort (Cohort 1) of Phase 3 REVEAL study
Angelman syndromesource ↗
Q3 2026
◆Timing GuidanceBepirovirsenPresentation
First regulatory decisions expected in Q3 2026
chronic hepatitis Bsource ↗
Q3 2026
Q3 2026
◆Enrollment CompleteobudanersenTrial
Expected completion of enrollment in adult cohort (Cohort 2) of Phase 3 REVEAL study
Angelman syndromesource ↗
Q3 2026
◆Enrollment UpdateobudanersenTrial
Adult cohort (Cohort 2) enrollment expected to complete in Q3 2026
Angelman syndromesource ↗
Jun 30, 2026
◆PDUFA DateOlezarsenApprovedRegulatory Filing
PDUFA target action date set for June 30, 2026
severe hypertriglyceridemia (sHTG)source ↗
Jun 25, 2026
▲Partnership / LicensezilganersenCorporate
License agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Alexander disease (AxD)source ↗
Jun 24, 2026
▲FDA ApprovalOlezarsenApprovedFDA Decision
FDA approval of TRYNGOLZA (olezarsen) for sHTG
severe hypertriglyceridemiasource ↗
Jun 8, 2026
Jun 4, 2026
◆Management ChangeCorporate
Lynne Parshall and Joseph Wender to retire from Board of Directors at end of term
May 28, 2026
▲Full ResultsBepirovirsenClinical Data
Pooled B-Well 1 and B-Well 2 topline results: 19% functional cure rate vs 0% placebo
chronic hepatitis Bsource ↗
Drug Pipeline Intelligence
B74
Pipeline Score $17.7B
Pipeline ValueUndervalued
Valuation Signal70
Drugs Scored4.7x
rNPV / MCap Top 95%
Mid Cap (rank 47 of 911)
Percentile RankIonis Pharmaceuticals, Inc. holds a solid B-grade pipeline (74/100), with $42.2B risk-adjusted pipeline value, led by ISIS 113715 in Type 2 Diabetes Mellitus (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ISIS 113715 Small molecule | Type 2 Diabetes Mellitus | Phase 2 | NCT00365781 | 23% | $4.7B | COMPLETED | 194 | - | - | Sep 1, 2006 | - | Oct 17, 2007 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
diranersen | early Alzheimer's disease | Phase 2 | 2026-05-14 | reduction in tau pathology and cognitive benefit | Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease Read More | |
diranersen | early Alzheimer's disease | Phase 2 | 2026-05-14 | reduction in tau pathology and cognitive benefit | Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease Read More | |
diranersen | early Alzheimer's disease | Phase 2 | 2026-05-14 | reduction in tau pathology and cognitive benefit | Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IONS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IONS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IONS▼ -23.9%on this news
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Ionis Pharmaceuticals and AstraZeneca reported that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy failed to meet its primary efficacy endpoint. The trial assessed cardiovascular mortality and recurrent clinical events but showed no significant difference compared to placebo. This outcome raises concerns about the drug's future prospects.
Read more →IONSIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Ionis Pharmaceuticals has completed enrollment in the pivotal cohort of the Phase 3 REVEAL study. This study is evaluating the efficacy of obudanersen in patients with Angelman syndrome. The completion of enrollment marks a significant step in the clinical trial process for this rare genetic disorder.
Read more →IONSIonis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Ionis Pharmaceuticals has entered into a licensing agreement with Recordati for the development of zilganersen, a treatment for Alexander disease (AxD). This agreement grants Recordati rights to market the drug in all countries outside the United States. This collaboration aims to advance the treatment options available for patients suffering from AxD.
Read more →IONSTRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
The FDA has approved TRYNGOLZA® (olezarsen) as the first treatment specifically designed to reduce triglycerides and the risk of acute pancreatitis in patients suffering from severe hypertriglyceridemia (sHTG). This approval represents a significant advancement in managing this serious condition, offering hope for improved patient outcomes.
Read more →IONSFINAL Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Ionis Pharmaceuticals has appointed Ludwig Hantson, Ph.D., to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry. His expertise is anticipated to support Ionis in its upcoming commercial launches and enhance its operational capabilities. Alongside this appointment, Ionis announced the retirement of two long-serving directors. The company is positioned for accelerated growth with a focus on its innovative pipeline in RNA-targeted medicines.
Read more →IONSIonis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Ionis Pharmaceuticals has appointed Ludwig Hantson, Ph.D., to its Board of Directors, effective immediately. Dr. Hantson brings over 30 years of experience in the biopharmaceutical sector, having held leadership roles at companies such as Alexion and Baxter. His expertise is expected to support Ionis as it prepares for new commercial launches and scales its operations.
Read more →IONSIonis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Read more →IONSIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
GSK, in partnership with Ionis, has announced that bepirovirsen has achieved unprecedented functional cure rates in treating chronic hepatitis B. This breakthrough has the potential to significantly change the current treatment landscape for the disease. The collaboration highlights the importance of innovative therapies in addressing chronic viral infections.
Read more →IONSIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
Biogen has announced topline results from the Phase 2 CELIA study of diranersen (BIIB080), which is the first study to show a reduction in tau pathology in patients with early Alzheimer's disease. Additionally, the study reported cognitive benefits, marking a significant advancement in Alzheimer's research. This collaboration with Ionis highlights the potential of diranersen in treating this condition.
Read more →IONSIonis to host 2026 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals has announced that it will host its 2026 virtual Annual Meeting of Stockholders. The meeting will provide shareholders with updates on the company's performance and strategic direction. Further details regarding the agenda and participation will be shared closer to the event date.
Read more →IONSIonis to present at upcoming investor conferences
Ionis Pharmaceuticals has announced its participation in several upcoming investor conferences, including the Bank of America Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in fireside chats, with live webcasts available for stakeholders. The company emphasizes its commitment to innovation in RNA-targeted therapies.
Read more →IONSIonis reports first quarter 2026 financial results and highlights progress on key programs
Ionis Pharmaceuticals reported a strong financial performance for Q1 2026, with a revenue increase of 87% compared to the previous year. The company is preparing for two major independent drug launches and has improved its financial guidance for the year. However, operating expenses have also risen, reflecting ongoing investments in commercialization efforts.
Read more →IONSIonis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
GSK has announced that the FDA accepted the NDA for bepirovirsen, an investigational treatment for chronic hepatitis B, for Priority Review and granted it Breakthrough Therapy designation. The drug demonstrated significant functional cure rates in Phase 3 trials. The PDUFA date is set for October 26, 2026, indicating a potential first-in-class treatment for a condition affecting millions.
Read more →IONSIonis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
Ionis Pharmaceuticals announced positive results from the pivotal study of zilganersen for Alexander disease at the AAN 2026 Annual Meeting. The study demonstrated significant stabilization of gait speed and improvements in gross motor function in children. Zilganersen showed favorable safety and tolerability, with an FDA action date set for September 2026.
Read more →IONSIonis to hold first quarter 2026 financial results webcast
Ionis Pharmaceuticals has announced that it will hold a webcast to discuss its financial results for the first quarter of 2026. The event aims to provide insights into the company's financial performance and future outlook. Further details regarding the timing and access to the webcast will likely be shared closer to the date.
Read more →IONSIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
Ionis Pharmaceuticals announced that the FDA has accepted its New Drug Application for zilganersen, aimed at treating Alexander disease. This investigational RNA-targeted medicine is under Priority Review, with a PDUFA target action date set for September 22, 2026. The acceptance highlights the urgency of addressing this rare neurological condition.
Read more →IONSIonis announces changes to Board of Directors
Ionis Pharmaceuticals announced changes to its Board of Directors, with Lynne Parshall and Joseph Wender retiring by June 2026. Peter Reikes will rejoin the board, bringing extensive financial and industry experience. Both retiring members have significantly contributed to the company over their long tenures. The transitions aim to support Ionis's growth and innovation in RNA-targeted therapies.
Read more →IONSIonis announces changes to Board of Directors - Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board
Ionis Pharmaceuticals announced upcoming changes to its Board of Directors, effective June 4, 2026. Lynne Parshall and Joseph Wender will retire, while Peter Reikes will rejoin the board. Parshall and Wender have each served for over two decades, contributing significantly to the company's development. Reikes' background includes roles at the FDA and other biotech firms, providing him with extensive experience to guide Ionis through its ongoing growth phase. The transition is seen as positive for the future of the company's governance.
Read more →IONSIonis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Ionis Pharmaceuticals announced new data for DAWNZERA™ (donidalorsen), the first RNA-targeted treatment for hereditary angioedema (HAE), to be presented at the 2026 AAAAI Annual Meeting. The data includes findings from Phase 3 studies, emphasizing DAWNZERA's ability to improve attack rates and quality of life for HAE patients. The presentation will feature eight posters detailing various aspects of treatment and patient experiences.
Read more →IONSOlezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals announced that the FDA has accepted the supplemental New Drug Application for olezarsen, aimed at treating severe hypertriglyceridemia (sHTG), for Priority Review. The PDUFA target action date is set for June 30, 2026. The decision is based on positive results from Phase 3 studies showing significant reductions in triglyceride levels and acute pancreatitis events. This designation highlights the urgent need for effective treatment options in this patient population.
Read more →IONS▼ -5.3%on this newsshared move
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
Ionis Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighting successful independent product launches and positive data readouts. The company is set for additional launches in 2026, including olezarsen and zilganersen, while also anticipating significant revenue growth. Ionis aims for cash flow breakeven by 2028, supported by its expanding pipeline.
Read more →IONSIonis updates time for fourth quarter and full year 2025 financial results webcast
Ionis Pharmaceuticals has announced a new start time for its fourth quarter and full year 2025 financial results webcast, moving it from 11:30 a.m. to 8:30 a.m. Eastern Time on February 25. The date of the call remains unchanged, and a replay will be available afterward. This change reflects the company's commitment to keeping stakeholders informed.
Read more →IONSIonis to hold fourth quarter and full year 2025 financial results webcast
Ionis Pharmaceuticals will hold a live webcast on February 25, 2025, to discuss its fourth quarter and full year financial results. The event will also highlight advancements in key programs. A replay will be available after the live session. Ionis continues to innovate in RNA-targeted therapies and gene editing.
Read more →IONSDAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Ionis Pharmaceuticals and Otsuka Pharmaceutical announced the European Commission's approval of DAWNZERA (donidalorsen) for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 and older. This approval follows positive results from Phase 3 studies showing significant reductions in attack rates. DAWNZERA is the first RNA-targeted therapy for HAE, highlighting a significant advancement in treatment options for this rare condition.
Read more →IONSIonis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - TRYNGOLZA (olezarsen) outperforms expectations, achieved 2025 prel
Ionis Pharmaceuticals has outlined a promising trajectory for 2026, aiming for significant value creation driven by the independent launches of TRYNGOLZA (olezarsen) and DAWNZERA (donidalorsen). The company reported strong preliminary sales for TRYNGOLZA, projecting peak net sales to exceed $2 billion. Additionally, Ionis has positive early data for bepirovirsen in chronic hepatitis B and anticipates five Phase 3 readouts this year. Despite the optimistic outlook, safety concerns and commercialization risks must be managed as the company advances its pipeline.
Read more →IONSIonis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B Primary endpoint met in both trials - Bepirovi
GSK, a partner of Ionis Pharmaceuticals, has announced positive topline results from two Phase 3 trials, B-Well 1 and B-Well 2, evaluating bepirovirsen for chronic hepatitis B. The trials met their primary endpoint, showing statistically significant functional cure rates in patients treated with bepirovirsen in combination with standard care. Bepirovirsen has the potential to be the first finite therapeutic option for chronic hepatitis B, targeting a significant global health challenge. Regulatory submissions are planned for 2026 to facilitate further development and approval.
Read more →IONSIonis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Ionis Pharmaceuticals has received Breakthrough Therapy designation from the FDA for zilganersen, aimed at treating Alexander disease, a severe neurological condition. This designation is based on promising results from a pivotal study showing significant improvements in gait speed. The company plans to submit a New Drug Application in early 2026.
Read more →IONSIonis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals has received Breakthrough Therapy designation from the FDA for olezarsen, aimed at reducing triglyceride levels in adults with severe hypertriglyceridemia. The designation is based on positive results from Phase 3 CORE and CORE2 studies, showing significant reductions in triglycerides and acute pancreatitis events. Olezarsen is expected to change the treatment landscape for this serious condition.
Read more →IONSIonis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes - Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity
Ionis Pharmaceuticals has announced a proposed offering of $700 million in Convertible Senior Notes due in 2030 as part of a strategy to refinance its existing 2026 Convertible Notes. The proceeds will be used for repurchasing or repaying the 2026 notes prior to their maturity. The offering is contingent on market conditions, and Ionis has indicated that it may repurchase a portion of the 2026 notes concurrently with this new offering. The company emphasizes that there are various risks involved, including those associated with market conditions and potential changes to its financial strategy.
Read more →IONS▼ -5.5%on this newsshared move
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions - Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels a
Ionis Pharmaceuticals announced groundbreaking results from the Phase 3 CORE and CORE2 studies of olezarsen, showing up to a 72% placebo-adjusted reduction in fasting triglyceride levels in patients with severe hypertriglyceridemia. Notably, the treatment also resulted in an 85% reduction in acute pancreatitis events. The findings were presented at the AHA Scientific Sessions and published in The New England Journal of Medicine. Ionis plans to submit a supplemental NDA for olezarsen by the end of the year, potentially expanding treatment options for this high-risk patient population.
Read more →IONSIonis reports third quarter 2025 financial results and highlights progress on key programs - TRYNGOLZA generated $32 million in net product sales in the third quarter 2025 - - DAWNZERA (donidalorsen) launch off to encour
Ionis Pharmaceuticals reported a strong financial performance for Q3 2025, with total revenue rising to $157 million, driven by sales of TRYNGOLZA. The company highlighted significant progress in its pipeline with positive Phase 3 results from olezarsen and zilganersen, paving the way for two independent launches in 2026. Ionis has also raised its financial guidance for the year, reflecting confidence in its growth strategy. Despite a reported operating loss of $160 million, the company anticipates reaching cash flow breakeven by 2028.
Read more →IONSIonis announces positive topline results from pivotal study of zilganersen in Alexander disease - First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare,
Ionis Pharmaceuticals announced positive topline results from its pivotal study of zilganersen for Alexander disease, marking the first successful demonstration of disease-modifying treatment for this rare neurological condition. The 50 mg dose of zilganersen showed significant improvements in gait speed and other key secondary endpoints, with a favorable safety profile. An NDA submission is planned for Q1 2026, as the company aims to initiate an Expanded Access Program for patients in need. The results present a potential breakthrough for treating a condition with no prior approved therapies.
Read more →IONS▲ +34.8%on this news
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) - Up to 72% (p 0.0001) placebo-adjusted mean reduction in fasting
Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies for olezarsen, targeting severe hypertriglyceridemia (sHTG). The drug achieved a notable 72% placebo-adjusted mean reduction in fasting triglycerides and an 85% reduction in acute pancreatitis events. Both studies included nearly 1,100 patients and showed favorable safety profiles. Ionis plans to submit a supplemental new drug application to the FDA by the end of the year.
Read more →IONSDAWNZERA (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema - DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disea
Ionis Pharmaceuticals has received FDA approval for DAWNZERA (donidalorsen), the first RNA-targeted prophylactic treatment for hereditary angioedema (HAE). The approval follows promising results from the Phase 3 OASIS-HAE study, which showed significant reductions in HAE attack rates. With self-administration options every 4 or 8 weeks, DAWNZERA aims to enhance treatment adherence and patient quality of life. Ionis plans to roll out DAWNZERA in the U.S. shortly, and will provide a suite of patient support services to ensure access and proper management.
Read more →IONSIonis reports second quarter 2025 financial results and highlights progress on key programs - TRYNGOLZA TM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angi
Ionis Pharmaceuticals reported its financial results for Q2 2025, revealing a significant increase in total revenue to $452 million compared to $225 million in Q2 2024. Key highlights include $19 million in net product sales from TRYNGOLZA and an anticipated approval for donidalorsen for hereditary angioedema in the coming month. Ionis also increased its financial guidance for 2025, citing strong performance and expectations for further advancements in its drug pipeline. The company is preparing for important Phase 3 study data expected in September 2025, potentially impacting future growth.
Read more →IONSIonis announces Dr. Richard Geary, chief development officer to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Ionis Pharmaceuticals announced that Dr. Richard Geary will retire as chief development officer in January 2026. Dr. Holly Kordasiewicz, currently senior vice president of neurology, will take over this role. Dr. Geary has been with the company for 30 years and has contributed to the public approval of six medicines. Kordasiewicz brings 20 years of experience in neurology drug development and will continue to advance Ionis' portfolio of neurological therapies.
Read more →IONSIonis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides - Olezarsen met the primary endpoint with a statistically significant mean reduction in triglyceri
Ionis Pharmaceuticals announced positive topline results from the Essence study of olezarsen, showing significant reductions in triglyceride levels in patients with moderate hypertriglyceridemia. The study achieved its primary endpoint with a placebo-adjusted reduction of 61% and 58% at 80 mg and 50 mg doses, respectively. Olezarsen also successfully met all key secondary endpoints and exhibited a favorable safety profile. Ionis plans to present these findings at a scientific conference, with further data expected from pivotal Phase 3 studies in Q3 2025.
Read more →IONSIonis reports first quarter 2025 financial results - Encouraging start to first independent launch with TRYNGOLZA TM - - On track for second independent launch with donidalorsen PDUFA
Ionis Pharmaceuticals reported financial results for the first quarter of 2025, highlighting a strong beginning to its independent launch of TRYNGOLZA for familial chylomicronemia syndrome. The company raised its financial guidance for the year by over 20%, attributing the increase to robust early performance and successful licensing transactions. Ionis also looks forward to a second independent product launch for donidalorsen, paired with upcoming Phase 3 results for olezarsen. However, the company continues to face significant operating losses, although they are showing signs of improvement in recent quarters.
Read more →IONSIonis and Ono announce global license agreement for sapablursen in polycythemia vera CARLSBAD, Calif., and Osaka, Japan
Ionis Pharmaceuticals and Ono Pharmaceutical Co. have entered a global license agreement granting Ono exclusive rights to develop and commercialize sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV). Ionis will receive an upfront payment of $280 million and the potential for additional earnings based on milestone achievements. Sapablursen is currently undergoing evaluation in a Phase 2 study and has received both Fast Track and orphan drug designations from the FDA. This partnership aims to enhance treatment availability for patients suffering from this rare hematologic condition.
Read more →IONSIonis and Ono Pharmaceutical announce global license agreement for sapablursen for polycythemia vera
Ionis and Ono Pharmaceutical announce global license agreement for sapablursen for polycythemia vera
Read more →IONSIonis reports fourth quarter and full year 2024 financial results - First independent launch underway following TRYNGOLZA TM approval - - Second independent launch on track with donidalorsen PDUFA
Ionis Pharmaceuticals reported its fourth quarter and full year 2024 financial results, showcasing a successful independent launch of TRYNGOLZA. The company exceeded its financial guidance for the year and projected over $600 million in revenue for 2025. With several independent drug launches planned, including donidalorsen, Ionis positions itself for future growth despite reporting an increased operating loss. The financial results reflect advancements in their drug pipeline and increased commercial activity.
Read more →IONSIonis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Read more →IONSIonis to present at 43rd Annual J.P. Morgan Healthcare Conference Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at...
Ionis Pharmaceuticals, Inc. announced that CEO Brett P. Monia will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will provide a company overview and will be available via live webcast. Ionis is recognized for its innovative RNA-targeted medicines and has a robust pipeline in various therapeutic areas.
Read more →IONSTRYNGOLZA (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce
Ionis Pharmaceuticals has announced the FDA approval of TRYNGOLZA (olezarsen) as the first treatment for adults with familial chylomicronemia syndrome (FCS), aimed at significantly reducing triglyceride levels in conjunction with a low-fat diet. The approval is based on successful results from the Phase 3 Balance trial, which indicated substantial reductions in triglycerides and acute pancreatitis events. This marked a significant milestone for both the company and patients, providing new hope for those affected by this rare genetic condition.
Read more →IONSTRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an ...
Ionis Pharmaceuticals has received FDA approval for TRYNGOLZA™ (olezarsen), the first treatment for adults with familial chylomicronemia syndrome (FCS). This medication significantly lowers triglyceride levels and reduces the risk of acute pancreatitis when used alongside a low-fat diet. The approval marks a significant advancement for patients suffering from this rare, life-threatening condition.
Read more →IONSIonis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:...
Ionis Pharmaceuticals will participate in several upcoming investor conferences, including Guggenheim's and UBS's events on November 13, 2024. Other conferences include Stifel, Jefferies, Citi, and Piper Sandler, scheduled throughout November and December. Live webcasts of the presentations will be available on their website, with replays accessible shortly after.
Read more →IONSIonis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Read more →IONSIonis reports third quarter 2024 financial results WAINUA TM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen
Ionis Pharmaceuticals reported positive developments in its third quarter 2024 results, highlighting the successful U.S. launch of WAINUA and its approval in the UK. The company is positioned for significant upcoming FDA decisions regarding olezarsen and donidalorsen, with expectations for positive Phase 3 data in the coming years. Despite an increase in operational losses compared to last year, Ionis raised its cash forecast, indicating a solid financial strategy to support ongoing and future projects.
Read more →IONSIonis reports third quarter 2024 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024....
Ionis Pharmaceuticals reported its third quarter 2024 financial results, highlighting the successful launch of WAINUA and positive regulatory feedback for olezarsen. The company reaffirmed its financial guidance and increased cash projections, while also noting significant progress in its Phase 3 pipeline. Despite a slight decrease in revenue and increased operating losses, Ionis remains optimistic about its future growth and product launches.
Read more →IONSIonis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Read more →IONSIonis to hold third quarter 2024 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to...
Ionis Pharmaceuticals will host a live webcast on November 6, 2024, at 11:30 a.m. ET to discuss its third quarter financial results. The event will be accessible online, and a replay will be available afterward. Ionis continues to innovate in RNA-targeted therapies and has a strong pipeline of medicines.
Read more →IONSWAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
Read more →IONSNew positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study ...
Ionis Pharmaceuticals announced new three-year data from the Phase 2 open-label extension study of donidalorsen, showing significant reductions in hereditary angioedema (HAE) attacks. The data will be presented at the 2024 ACAAI Annual Scientific Meeting. Donidalorsen demonstrated high disease control and quality of life improvements across most patients.
Read more →IONSZilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Read more →IONSIonis announces pricing of $500.3 million public offering
Ionis announces pricing of $500.3 million public offering
Read more →IONSIonis announces proposed public offering of common stock Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis...
Ionis Pharmaceuticals has announced a proposed public offering of $500 million in common stock, with an option for underwriters to purchase an additional $75 million. The funds will support commercial launches, late-stage clinical programs, and R&D activities. The offering is contingent on market conditions, and details will be filed with the SEC.
Read more →IONSIonis reports second quarter 2024 financial results WAINUA TM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA
Ionis Pharmaceuticals announced its financial results for Q2 2024, highlighting the successful U.S. launch of WAINUA and its approval in Canada. The company is making progress with its pipeline, including positive Phase 3 data for donidalorsen and an upcoming PDUFA decision for olezarsen. Despite operating losses and a decrease in cash reserves, Ionis remains focused on strategic investments in their promising pipeline while maintaining their 2024 financial guidance.
Read more →IONSIonis reports second quarter 2024 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2024....
Ionis Pharmaceuticals reported a strong financial performance for Q2 2024, with a 20% increase in revenue compared to the same period last year. The company highlighted successful launches and positive Phase 3 data for key products, including WAINUA and donidalorsen. Despite a reported net loss, Ionis remains on track with its financial guidance and strategic investments in its pipeline.
Read more →IONS▲ +5.8%on this news
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Read more →IONSIonis to hold second quarter 2024 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, August 1st at 11:30 a.m. Eastern Time to...
Ionis Pharmaceuticals, Inc. announced a live webcast scheduled for August 1, 2024, at 11:30 a.m. Eastern Time to discuss its second quarter financial results. The webcast will be accessible online, and a replay will be available for a limited time. Ionis continues to innovate in RNA-targeted medicines and gene editing.
Read more →IONSIonis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it has completed enrollment in the pivotal trial of zilganersen (ION373), an...
Ionis Pharmaceuticals has completed enrollment in a pivotal trial for zilganersen, an investigational medicine aimed at treating Alexander disease, a rare neurological disorder. The trial will assess the efficacy of zilganersen in improving gait speed among participants. Topline data is expected in the second half of 2025, marking a significant milestone in addressing this life-threatening condition.
Read more →IONSIonis announces webcast to report HALOS study results for ION582 in Angelman syndrome Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss ...
Ionis Pharmaceuticals will host a live webcast on July 22, 2024, to discuss results from the Phase 1/2a HALOS study of ION582 for Angelman syndrome. The results will also be presented at the Angelman Syndrome Foundation Family Conference on July 24 in Sandusky, Ohio. This event highlights Ionis's commitment to advancing RNA-targeted therapies.
Read more →IONS▲ +5.2%on this news
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Read more →IONSIonis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) ...
Ionis Pharmaceuticals has entered an expanded licensing agreement with Otsuka Pharmaceutical for donidalorsen, an investigational treatment for hereditary angioedema. Otsuka will handle commercialization in Asia-Pacific and Europe, while Ionis retains U.S. rights. The agreement includes a $20 million upfront payment and potential milestone payments. Positive Phase 3 results for donidalorsen were recently reported.
Read more →IONSIonis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema Otsuka will be responsible for commercialization efforts for donidalorsen across
Ionis Pharmaceuticals has announced an expanded licensing agreement with Otsuka Pharmaceutical for donidalorsen, an investigational therapy for hereditary angioedema (HAE). Under this agreement, Otsuka will be responsible for developing and commercializing the medicine in the Asia-Pacific region, following similar efforts in Europe. Ionis plans to file for FDA approval later this year and has reported positive Phase 3 trial results, positioning donidalorsen as a potentially significant treatment option for HAE. The deal includes a $20 million upfront payment with milestone payments based on regulatory achievements.
Read more →IONSIonis to present at TD Cowen Genetic Medicines & RNA Summit Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic...
Ionis Pharmaceuticals will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024. The event will be accessible via a live webcast on their website, with a replay available shortly after. Ionis continues to lead in RNA-targeted medicines and has a robust pipeline focused on serious diseases.
Read more →IONSIonis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life...
Ionis Pharmaceuticals announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen, an investigational treatment for hereditary angioedema (HAE). The studies demonstrated significant reductions in monthly HAE attack rates and improved quality of life for patients. Donidalorsen was well-tolerated, and the company plans to pursue regulatory approval based on these findings.
Read more →IONSIonis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema Donidalorsen delivered significant and sustained reductions in HAE atta
Ionis Pharmaceuticals announced promising results from the Phase 3 OASIS-HAE and OASISplus studies, highlighting the efficacy of donidalorsen in reducing hereditary angioedema (HAE) attack rates. Patients treated with donidalorsen experienced over 90% improvement in attack frequency after one year, with 84% preferring this treatment to their prior therapies. The company plans to pursue regulatory approval for donidalorsen following these findings, which will be presented at the upcoming EAACI Annual Congress. Donidalorsen is designed to lower prekallikrein production, which is linked to HAE attacks.
Read more →IONSIonis to hold donidalorsen Phase 3 data webcast Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, May 31th at 8:00 a.m. Eastern Time to discuss...
Ionis Pharmaceuticals will host a live webcast on May 31, 2024, to discuss the Phase 3 results of donidalorsen from the OASIS-HAE and OASISplus studies. These results will be presented at the 2024 EAACI Annual Meeting in Valencia, Spain. The webcast will be accessible online, with a replay available for a limited time.
Read more →IONSNew data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3...
Ionis Pharmaceuticals announced new subgroup analyses from the Phase 3 NEURO-TTRansform study of WAINUA (eplontersen), which will be presented at the 2024 International Symposium on Amyloidosis. The study shows consistent benefits in neuropathy impairment and quality of life for patients with hereditary transthyretin-mediated amyloidosis. WAINUA was approved by the FDA in December 2023 for treating hATTR-PN.
Read more →IONSIonis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
Read more →IONSIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Read more →IONSIonis to host 2024 virtual Annual Meeting of Stockholders Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ...
Ionis Pharmaceuticals will hold its 2024 virtual Annual Meeting of Stockholders on June 6, 2024. All stockholders of record as of April 8, 2024, are invited to participate. CEO Brett P. Monia will provide a corporate update followed by a Q&A session. Stockholders can submit questions in advance via email.
Read more →IONSIonis reports first quarter 2024 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter ended March 31, 2024....
Ionis Pharmaceuticals reported its Q1 2024 financial results, highlighting a successful launch of WAINUA and positive Phase 3 data for donidalorsen. The company reaffirmed its financial guidance for the year, despite an increase in operating expenses and a net loss of $143 million. Ionis continues to advance its pipeline with multiple regulatory submissions and upcoming data readouts.
Read more →IONSIonis reports first quarter 2024 financial results WAINUA TM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase
Ionis Pharmaceuticals has reported its first quarter 2024 financial results, highlighting the successful launch of WAINUA for hereditary ATTR polyneuropathy. The company submitted an NDA for olezarsen to the FDA and anticipates positive data from Phase 3 donidalorsen studies. While operating expenses are rising, Ionis remains on track to achieve its financial guidance for 2024, bolstered by new royalty revenues. Additionally, preparations for regulatory submissions in Europe and Canada are underway.
Read more →IONSIonis Publishes 2023 Corporate Responsibility Report Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report...
Ionis Pharmaceuticals has published its 2023 Corporate Responsibility Report, outlining its commitment to improving patient lives and operating sustainably. The report highlights the approval of two new medicines and the establishment of strategic pillars for corporate responsibility. Ionis emphasizes its ongoing efforts in innovation, employee empowerment, and environmental responsibility.
Read more →IONSIonis to hold first quarter 2024 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss ...
Ionis Pharmaceuticals, Inc. will host a live webcast on May 7, 2024, at 11:30 a.m. ET to discuss its first quarter financial results. The webcast will be accessible online, and a replay will be available for a limited time. Ionis is recognized for its innovative RNA-targeted medicines and has a robust pipeline.
Read more →IONSIonis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and sho
Ionis Pharmaceuticals announced positive results from the Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome (FCS), showing significant reductions in triglycerides and acute pancreatitis events. The study reported robust efficacy and a favorable safety profile, suggesting that olezarsen could become the standard of care for patients with FCS. Ionis plans to pursue regulatory approval based on these encouraging results, highlighting the potential for olezarsen to alleviate serious complications associated with this genetic condition.
Read more →IONSIonis to hold olezarsen Phase 3 data webcast Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to...
Ionis Pharmaceuticals will host a live webcast on April 8 to present the results of the olezarsen Phase 3 Balance study for familial chylomicronemia syndrome. This event coincides with the 2024 American College of Cardiology Annual Meeting. The webcast will be accessible online, with a replay available for a limited time.
Read more →IONSPositive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present positive Phase 3 Balance results in patients with familial...
Ionis Pharmaceuticals announced positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome (FCS). The study demonstrated significant reductions in triglyceride levels and acute pancreatitis events. Olezarsen, which has received Fast Track designation from the FDA, will be presented at the 2024 ACC Annual Meeting. This treatment addresses a critical need, as there are no approved therapies for FCS.
Read more →IONSIonis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Read more →IONSIonis announces new chief global product strategy officer to lead next phase of commercial growth
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Read more →IONSIonis reports fourth quarter and full year 2023 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the fourth quarter and full year ended December 31,...
Ionis Pharmaceuticals reported strong financial results for Q4 and full year 2023, highlighting significant revenue growth and two FDA approvals. The company is advancing its pipeline with positive Phase 3 data for olezarsen and donidalorsen, while preparing for launches and regulatory submissions. Despite increased operating expenses, Ionis expects continued growth in 2024.
Read more →IONSIonis reports fourth quarter and full year 2023 financial results WAINUA TM approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, prepari
Ionis Pharmaceuticals reported strong financial results for Q4 and the full year 2023, achieving significant revenue increases due to its advancing pipeline and FDA approvals, including WAINUA's launch for hereditary ATTR polyneuropathy. The company revealed positive Phase 3 data for its drugs olezarsen and donidalorsen, which are set for regulatory submissions. Looking ahead, Ionis expects continued growth and revenue generation in 2024, while also facing increased operating expenses and long-term liabilities related to royalties. Their CEO reiterated the commitment to delivering innovative medicines and technology advancements.
Read more →IONS▼ -7.7%on this newsshared move
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Read more →IONSEplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Read more →IONSIonis to hold fourth quarter and full year 2023 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to ...
Ionis Pharmaceuticals will hold a live webcast on February 21, 2024, at 11:30 a.m. ET to discuss its fourth quarter and full year 2023 financial results. The event will be accessible online, with a replay available for a limited time. Ionis continues to innovate in RNA-targeted therapies and has a robust pipeline.
Read more →IONSIonis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema Donidalorsen met the primary endpoint with a statistically significant reductio
Ionis Pharmaceuticals announced favorable topline results from the Phase 3 OASIS-HAE study of donidalorsen for patients with hereditary angioedema. The treatment showed statistical significance in reducing the rate of angioedema attacks and met its primary endpoint. There were no serious adverse events reported, indicating a positive safety profile. Following these results, Ionis plans to submit a New Drug Application to the FDA and Otsuka is preparing to apply for marketing authorization in Europe.
Read more →IONSIonis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with...
Ionis Pharmaceuticals announced positive topline results from the Phase 3 OASIS-HAE study of donidalorsen, an investigational treatment for hereditary angioedema (HAE). The study showed a statistically significant reduction in the rate of HAE attacks in patients treated every 4 or 8 weeks. Donidalorsen also exhibited a favorable safety profile, prompting Ionis to prepare a New Drug Application for FDA submission.
Read more →IONSIonis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Read more →IONSWAINUA (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis U.S. FDA approval based on Phase 3 NEURO-TTRansform results sh
Ionis Pharmaceuticals announced that the FDA has granted approval for WAINUA (eplontersen) to treat adults with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). This approval is based on positive results from the Phase 3 NEURO-TTRansform study. WAINUA is notable for allowing self-administration via an auto-injector, marking a significant advancement in the management of this debilitating disease. The treatment offers improvements in quality of life and neuropathy impairment, although monitoring for vitamin A levels is necessary due to potential adverse effects.
Read more →IONSWAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's...
Ionis Pharmaceuticals has received FDA approval for WAINUA (eplontersen), a treatment for adults with hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). The approval is based on positive results from the Phase 3 NEURO-TTRansform study, which showed significant benefits in halting disease progression and improving quality of life. WAINUA will be available in the U.S. starting January 2024, marking a significant milestone for patients suffering from this debilitating condition.
Read more →IONSIonis to present at 42nd Annual J.P. Morgan Healthcare Conference Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at...
Ionis Pharmaceuticals, Inc. announced that its CEO, Brett P. Monia, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be accessible via a live webcast, with replays available shortly after. Ionis continues to lead in RNA-targeted therapies with a robust pipeline.
Read more →IONSIonis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema - Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients - Ionis
Ionis Pharmaceuticals has entered a licensing agreement with Otsuka Pharmaceutical for exclusive commercialization of donidalorsen in Europe, targeted at treating hereditary angioedema (HAE). Ionis will continue its role in the non-clinical and clinical development of donidalorsen while Otsuka manages regulatory and commercialization efforts. The agreement includes an upfront payment of $65 million to Ionis along with potential milestone payments. Positive results from ongoing trials are expected to further validate the product's efficacy ahead of pivotal Phase 3 results set to be announced in early 2024.
Read more →IONSIonis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) ...
Ionis Pharmaceuticals has entered a licensing agreement with Otsuka Pharmaceutical for donidalorsen, an investigational treatment for hereditary angioedema (HAE). Otsuka will commercialize the drug in Europe, while Ionis retains development responsibilities and plans to launch it in the U.S. if approved. Phase 3 results are expected in the first half of 2024.
Read more →IONSIonis announces the appointment of Michael Yang to Board of Directors
Ionis Pharmaceuticals announced the appointment of Michael Yang to its Board of Directors, increasing total board members to 10. Yang brings over 20 years of experience in the biopharmaceutical sector, having held leadership positions at companies like ViaCyte and Acadia Pharmaceuticals. His expertise in launching new products and expanding global revenues is expected to complement Ionis' scientific and business strategies as the company enters a new growth phase. The leadership looks forward to Yang's contributions to the board and overall company objectives.
Read more →IONSIonis announces the appointment of Michael Yang to Board of Directors Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis...
Ionis Pharmaceuticals has appointed Michael Yang to its Board of Directors, expanding the board to ten members. Yang, with over 20 years of experience in the biopharmaceutical industry, previously held leadership roles at ViaCyte and Acadia Pharmaceuticals. His expertise is expected to contribute significantly as Ionis enters its next growth phase.
Read more →IONSIonis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing...
Ionis Pharmaceuticals announced the completion of enrollment in the HALOS Phase 1/2a trial for ION582, aimed at treating Angelman syndrome. Preliminary findings show that ION582 has been well tolerated and indicates encouraging EEG activity trends and clinical improvements. Full results are expected in mid-2024, with the trial continuing into a long-term extension phase.
Read more →IONSIonis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from an ongoing Phase 2 open-label extension (OLE) study evaluating the...
Ionis Pharmaceuticals has announced positive results from a Phase 2 open-label extension study of donidalorsen, showing a 96% reduction in hereditary angioedema attack rates over two years. Patients reported significant improvements in quality of life, and the treatment was well tolerated. The company anticipates topline Phase 3 results in the first half of 2024.
Read more →IONSIonis reports third quarter 2023 financial results Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients w
Ionis Pharmaceuticals has reported its third-quarter financial results for 2023, highlighting promising data from the Phase 3 study of Oleazrsen, which demonstrated significant triglyceride reduction and lowered pancreatitis attacks. Eplontersen's marketing applications are under review in Europe and Canada, with a potential approval date in the U.S. set for December 2023. The company is on target to meet its financial guidance with a strong cash reserve exceeding $2 billion, facilitating continued investment in its pipeline of therapies.
Read more →IONSIonis reports third quarter 2023 financial results Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the third quarter of 2023....
Ionis Pharmaceuticals reported its third quarter 2023 financial results, highlighting positive data from the Phase 3 studies of eplontersen and olezarsen. Eplontersen is under review for U.S. approval, while olezarsen demonstrated significant efficacy in lowering triglycerides. Despite a strong cash position, the company reported increased operating expenses and a wider loss from operations compared to the previous year.
Read more →IONSIonis to hold third quarter 2023 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, November 2nd at 11:30 a.m. Eastern Time to...
Ionis Pharmaceuticals, Inc. will host a live webcast on November 2, 2023, at 11:30 a.m. ET to discuss its third quarter financial results. The event will be accessible online, and a replay will be available afterward. Ionis continues to lead in RNA-targeted therapies with a strong pipeline.
Read more →IONSIonis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines...
Ionis Pharmaceuticals showcased significant advancements during its Innovation Day, emphasizing its robust pipeline and commercial capabilities. The company plans to introduce four new neurology medicines by the end of 2024 and has received positive Phase 3 results for olezarsen. With a strong financial position, Ionis is poised for substantial revenue growth and independent commercial launches.
Read more →IONSEplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Read more →IONSIonis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered an agreement with Roche for two undisclosed early-stage programs for...
Ionis Pharmaceuticals has announced a partnership with Roche to develop two early-stage RNA-targeted programs for Alzheimer's and Huntington's diseases. Roche will gain exclusive rights to develop and commercialize these investigational medicines, while Ionis will receive an upfront payment of $60 million. This collaboration builds on a decade-long relationship between the two companies.
Read more →IONSIonis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational
Ionis Pharmaceuticals has entered an agreement with Roche to develop two early-stage RNA-targeted programs for Alzheimer's and Huntington's diseases. Roche will have exclusive worldwide rights to these investigational medicines, responsible for their clinical development and commercialization upon regulatory approval. The collaboration builds on a decade-long partnership, aiming to combine Ionis' innovative technology with Roche's extensive experience in neuroscience. Ionis will receive a $60 million upfront payment and will potentially benefit from other milestone royalties.
Read more →IONS▲ +8.5%on this newsshared move
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute...
Ionis Pharmaceuticals announced positive topline results from the Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome (FCS). The study demonstrated a statistically significant reduction in triglyceride levels and a complete elimination of acute pancreatitis events in treated patients. Ionis plans to submit a New Drug Application to the FDA in early 2024, marking a potential breakthrough for FCS treatment.
Read more →IONS▲ +8.5%on this newsshared move
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels
Ionis Pharmaceuticals announced positive topline results from the Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome (FCS). The drug demonstrated a significant reduction in triglyceride levels and achieved a 100% reduction in acute pancreatitis events compared to placebo. A New Drug Application with the FDA is planned for early 2024. However, the lower 50 mg dose did not show statistical significance in triglyceride lowering, and one death unrelated to the drug was reported during the study.
Read more →IONS▲ +5.4%on this news
Ionis to host investor and analyst day event Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and analyst day on Wednesday, October 4. The event will take ...
Ionis Pharmaceuticals is set to host an investor and analyst day on October 4, 2023, at the Westin New York Grand Central. The event will feature presentations from Ionis leadership and notable key opinion leaders, including experts from Columbia University and UCLA. Participants can register for the event and submit questions in advance.
Read more →IONSIonis reports second quarter 2023 financial results – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2023. Financial results are...
Ionis Pharmaceuticals reported a strong financial performance for Q2 2023, with a 40% increase in revenue driven by partner payments. The company is advancing its pipeline, particularly with eplontersen, which has shown positive Phase 3 results for ATTRv-PN. Ionis remains on track to meet its financial guidance for the year, supported by a robust cash position of $2.4 billion.
Read more →IONSIonis reports second quarter 2023 financial results Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Ionis Pharmaceuticals reported its second-quarter 2023 financial results, highlighting positive data for eplontersen in treating ATTRv-PN. The company is on track to meet its 2023 financial guidance with significant revenue growth driven by partnered programs. Despite higher operating expenses and a loss from operations, Ionis's late-stage pipeline and increasing licensing revenue suggest a strong future outlook. Key upcoming events include the potential approval of eplontersen by December 2023.
Read more →IONSIonis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 card
Ionis Pharmaceuticals has announced a collaboration with Novartis for developing a novel Lp(a)-targeting therapy aimed at treating cardiovascular disease. This partnership builds on their existing work with pelacarsen, which is currently in a Phase 3 study. Ionis will receive $60 million upfront and may earn further milestone payments. This next generation program is expected to leverage Ionis' RNA-targeting platform technologies to potentially improve efficacy for patients with elevated Lp(a) levels, which are linked to high cardiovascular risk.
Read more →IONSIonis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered a collaboration and license agreement with Novartis for the discovery, ...
Ionis Pharmaceuticals has announced a collaboration with Novartis to develop a novel treatment targeting lipoprotein(a) for cardiovascular disease. This partnership builds on their existing work with pelacarsen, currently in a Phase 3 study. Ionis will receive a $60 million upfront payment and could earn additional milestone payments. The new compound aims to leverage advanced RNA-targeting technologies.
Read more →IONSIonis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes...
Ionis Pharmaceuticals has completed enrollment in the Phase 3 CARDIO-TTRansform study, the largest study of its kind for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), involving over 1,400 patients. The study evaluates eplontersen, an investigational drug aimed at reducing cardiovascular events in this patient population. Results are expected in the first half of 2025.
Read more →IONSIonis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights...
Ionis Pharmaceuticals has expanded its collaboration with AstraZeneca to grant exclusive rights for the commercialization of eplontersen in Latin America. This follows AstraZeneca's existing rights for other regions outside the U.S. Both companies will continue to jointly develop eplontersen in the U.S., with regulatory approvals underway for its use in treating transthyretin amyloidosis.
Read more →IONSIonis to hold second quarter 2023 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, August 9th at 11:30 a.m. Eastern Time to...
Ionis Pharmaceuticals will host a live webcast on August 9, 2023, at 11:30 a.m. ET to discuss its second quarter financial results. The event will be accessible online, and a replay will be available afterward. Ionis continues to lead in RNA-targeted therapies with a strong pipeline.
Read more →IONSEplontersen continued to show improvement in ATTRv-PN through 85 weeks Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 wee
Ionis Pharmaceuticals has announced positive topline results from the Phase 3 NEURO-TTRansform study, demonstrating that eplontersen continued to improve symptoms in patients with hereditary transthyretin-mediated amyloid polyneuropathy over 85 weeks. At this point, the treatment maintained a reduction in serum TTR concentration and improved patient-reported quality of life. The results further support eplontersen as a promising treatment option for this underserved patient population. The company is working towards regulatory approvals in the U.S. and internationally.
Read more →IONSEplontersen continued to show improvement in ATTRv-PN through 85 weeks Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with...
Ionis Pharmaceuticals announced positive topline results from the Phase 3 NEURO-TTRansform study, showing that eplontersen continues to improve quality of life and halt disease progression in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) over 85 weeks. The drug demonstrated a sustained reduction in serum TTR concentration and a favorable safety profile. Regulatory approval efforts are underway in the U.S. and Europe.
Read more →IONSIonis prices private placement of convertible senior notes
Ionis Pharmaceuticals has announced the pricing of a private placement of $500 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028. The offering is aimed at qualified institutional buyers and includes an option for initial purchasers to acquire an additional $75 million in notes. The company anticipates that proceeds will be mainly utilized to repurchase existing convertible senior notes due in 2024, thereby enhancing its financial position as it moves towards maturity. The offering is expected to close on June 12, 2023, pending standard closing conditions.
Read more →IONSIonis announces proposed private placement of convertible notes
Ionis Pharmaceuticals announced its plan to offer $500 million in convertible senior notes due in 2028, subject to prevailing market conditions. The company intends to utilize the proceeds primarily for repurchasing existing 2024 notes and for general corporate purposes. The notes will remain unsecured and will accrue interest payable semiannually. The offering indicates investor confidence, although market conditions may impact execution and terms.
Read more →IONSIonis announces positive donidalorsen late-stage clinical progress in HAE
Ionis announces positive donidalorsen late-stage clinical progress in HAE
Read more →IONSIonis reports first quarter 2023 financial results QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data
Ionis Pharmaceuticals reported its first quarter 2023 financial results, highlighting the approval of QALSODY for SOD1-ALS and positive Phase 3 data for eplontersen. Despite ongoing investment in its growing pipeline, the company faced challenges with a loss from operations increasing year-over-year and a decline in total revenue. Ionis holds a robust late-stage pipeline and plans to maintain its financial guidance for 2023. The firm sees potential growth from eplontersen, positioned as a significant treatment for ATTRv-PN patients.
Read more →IONSFDA approves QALSODY (tofersen) as the first treatment targeting a genetic cause of ALS Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS
The FDA has approved QALSODY (tofersen) as the first targeted treatment for amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene. The approval, granted under accelerated conditions, is based on clinical trial results that showed a reduction in neurofilament light chain levels in patients. However, the ongoing Phase 3 ATLAS trial will serve to confirm the drug’s clinical benefits. Despite its potential, the treatment is associated with serious side effects, including various neurologic conditions.
Read more →IONSEplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks NEURO-TTRansform study met all co-primary and secondary endpoints Positive results
Ionis Pharmaceuticals announced that their investigational drug eplontersen met all primary and secondary endpoints in the Phase 3 NEURO-TTRansform study for treating hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The study, presented at the 2023 AAN Annual Meeting, demonstrated substantial and sustained improvements in neuropathy impairment and quality of life over 66 weeks compared to an external placebo group. Despite the drug's promising results, it is still undergoing regulatory approval processes in the U.S. and other regions.
Read more →IONSIonis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality
Ionis Pharmaceuticals announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of eplontersen for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The treatment met its primary endpoints, demonstrating significant efficacy in reducing TTR levels and improving patients' neuropathy and quality of life. Following these results, Ionis and partner AstraZeneca are pursuing regulatory approval, with the FDA accepting a New Drug Application for eplontersen aimed at treating this debilitating disease. Detailed results will be presented at the upcoming American Academy of Neurology Annual Meeting.
Read more →IONSIonis announces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
Ionis announces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
Read more →IONSIonis reports fourth quarter and full year 2022 financial results Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarse
Ionis Pharmaceuticals announced its fourth quarter and full year 2022 financial results, including the submission of the eplontersen NDA to the FDA. The company reported a net loss for the year and increased operating expenses, but also highlighted its goal of advancing its late-stage pipeline with new Phase 3 programs. Despite financial challenges, Ionis provided optimistic guidance for 2023, anticipating significant revenue from its commercial portfolio and partner programs. The company has secured additional funding to support its R&D efforts and commercial readiness for new therapies.
Read more →IONSIonis announces GSK has advanced bepirovirsen into Phase 3 development
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
Read more →IONSIonis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
Read more →IONS▼ -8.1%on this news
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Read more →IONSIonis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
Read more →IONSIonis partners with Metagenomi to add gene editing to its broad technology platform
Ionis partners with Metagenomi to add gene editing to its broad technology platform
Read more →IONSIonis reports third quarter financial results Advanced key priorities: initiated manufacturing infrastructure project to support growth Increased 2022 cash and investments guidance
Ionis reports third quarter financial results Advanced key priorities: initiated manufacturing infrastructure project to support growth Increased 2022 cash and investments guidance CARLSBAD, Calif., November 9, 2022 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company")
Read more →IONSIonis reports third quarter financial results
Ionis reports third quarter financial results
Read more →IONSIonis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
Read more →IONSIonis announces plan for new manufacturing facility in Oceanside, Calif.
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
Read more →IONSIonis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
Read more →IONSIonis reports second quarter financial results and recent business achievements Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22 Tofersen NDA under priority review, PDUFA
Ionis reports second quarter financial results and recent business achievements Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22 Tofersen NDA under priority review, PDUFA January 25, 2023 Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen
Read more →IONSIonis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Read more →IONSIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LEO SHUMACHER, derivatively on behalf ) of IONIS PHARMACEUTICALS, INC., ) ) Plaintiff, ) ) v. ) JOSEPH LOSCALZO, M.D., PH.D., ) BRETT P. MONIA, PH.D., SPENCER R. ) BERTHE
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LEO SHUMACHER, derivatively on behalf ) of IONIS PHARMACEUTICALS, INC., ) ) Plaintiff, ) ) v. ) JOSEPH LOSCALZO, M.D., PH.D., ) BRETT P. MONIA, PH.D., SPENCER R. ) BERTHELSEN, M.D., ALLENE M. DIAZ, ) MICHAEL HAYDEN
Read more →IONSIonis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study - Positive data from a Phase 2 study of IONIS-FB-L Rx support further development for treatment of patients with IgA nephr
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study CARLSBAD, Calif., July 11, 2022 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and advance IONIS-FB-LRx, an inves
Read more →IONS▲ +6.1%on this news
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Eplontersen showed stat
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) CARLSBAD, Calif., June 21, 2022 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today
Read more →IONSIonis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Read more →IONSIonis reports first quarter financial results and recent business achievements On track to achieve 2022 financial guidance Webcast today
Ionis reports first quarter financial results and recent business achievements On track to achieve 2022 financial guidance Webcast today, May 4, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 4, 2022 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial
Read more →IONSBiogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Read more →IONSIonis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Read more →IONS▲ +5.7%on this news
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements Exceeded 2021 financial guidance with revenues of more than $800 million Webcast today
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements Exceeded 2021 financial guidance with revenues of more than $800 million Webcast today, February 24, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., February 24, 2022 - Ionis
Read more →IONSPfizer and Ionis announce discontinuation of vupanorsen clinical development program
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
Read more →IONSBiogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Read more →IONS▲ +11.2%on this news
Ionis and AstraZeneca to develop and commercialize eplontersen Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market The companies will jointly develop and comme
Ionis and AstraZeneca to develop and commercialize eplontersen CARLSBAD, Calif., Dec. 6, 2021 - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration agreement with AstraZeneca to develop
Read more →IONSIonis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen Study met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol (no
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen CARLSBAD, Calif., Nov. 24, 2021 - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGP
Read more →IONSIonis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Read more →IONSIonis reports third quarter 2021 financial results and recent business achievements Olezarsen (IONIS-APOCIII-L Rx ) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx ) Phase 2 data to be pre
Ionis reports third quarter 2021 financial results and recent business achievements Olezarsen (IONIS-APOCIII-LRx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-LRx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track fo
Read more →IONSIonis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Read more →IONS▼ -13.8%on this news
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS CARLSBAD, Calif., Oct. 17, 2021 - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB
Read more →IONSIonis reports second quarter 2021 financial results and recent business achievements Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics' techno
Ionis reports second quarter 2021 financial results and recent business achievements Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics' technology potentially expands LICA technology capabilities Web
Read more →IONSIonis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
Read more →IONSIonis announces changes to its board of directors at annual meeting of stockholders - Joseph Loscalzo, M.D., Ph.D., appointed chairman of the board - Ionis founder and Executive Chairman Stanley T. Crooke, M.D., Ph.D., r
Ionis announces changes to its board of directors at annual meeting of stockholders CARLSBAD, Calif., June 2, 2021 - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the bo
Read more →IONSIonis reports first quarter 2021 financial results and recent business achievements On track to achieve 2021 guidance Webcast today
Ionis reports first quarter 2021 financial results and recent business achievements On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial
Read more →IONSIonis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Read more →IONSIonis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
Read more →IONSIonis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx ) - Dosing to stop in Phase III clinical study of tominersen and paused in the open-label extension study (GEN-EXTEND) - The Phase I
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTTRx) CARLSBAD, Calif., March 22, 2021 - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominerse
Read more →IONSIonis reports fourth quarter and full year 2020 financial results and recent business achievements Achieved 2020 financial guidance 2021 guidance reflects increased investments in wholly owned pipeline to drive future re
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements Achieved 2020 financial guidance 2021 guidance reflects increased investments in wholly owned pipeline to drive future revenue growth Webcast today, February 24, 2021, at 9:00 a.
Read more →IONSIonis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Read more →IONSStanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation CARLSBAD, Calif., Dec. 17, 2020 - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive
Read more →IONSIonis highlights achievements, commercial strategy and technology advancements at Investor Day - Prioritizing and preparing its growing Ionis-owned pipeline for commercialization - Potential to launch 6+ new products in
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day CARLSBAD, Calif., Dec. 8, 2020 - At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and outlined its
Read more →IONSIonis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
Read more →IONSIonis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
Read more →IONSIonis reports third quarter 2020 financial results and recent business achievements
Ionis reports third quarter 2020 financial results and recent business achievements
Read more →IONSIonis Pharmaceuticals completes acquisition of Akcea Therapeutics
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company CARLSBAD, Calif., Oct. 12, 2020 /PRNewswire/ Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acq
Read more →IONSIonis treatment for Alexander disease receives orphan drug designation from U.S. FDA
Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
Read more →IONSNew England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
Read more →IONSIonis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash Transaction drives efficiencies, enhance
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics CARLSBAD, Calif., and BOSTON, August 31, 2020 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agr
Read more →IONSIonis reports second quarter 2020 financial results and recent business achievements On track to achieve 2020 objectives and financial guidance Webcast today
Ionis reports second quarter 2020 financial results and recent business achievements On track to achieve 2020 objectives and financial guidance Webcast today, August 5, 2020, at 11:30 a.m. Eastern Time CARLSBAD, Calif., August 5, 2020 - Ionis Pharmaceuticals, Inc. (Nasdaq: ION
Read more →IONSIonis reports first quarter 2020 financial results and recent business achievements On track to achieve 2020 financial guidance Webcast today
Ionis reports first quarter 2020 financial results and recent business achievements On track to achieve 2020 financial guidance Webcast today, May 6, 2020, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 6, 2020 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its
Read more →IONSIonis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Read more →IONSIonis provides fourth quarter and full year 2019 financial results 2019 revenues nearly doubled to more than $1.1 billion Exceeded improved 2019 guidance 2020 guidance reflects investment in strategic priorities Webcast
Ionis provides fourth quarter and full year 2019 financial results 2019 revenues nearly doubled to more than $1.1 billion Exceeded improved 2019 guidance 2020 guidance reflects investment in strategic priorities Webcast today, February 26, 2020, at 11:30 a.m. Eastern Time CA
Read more →IONSIonis treatment for Alexander disease granted orphan drug status from EMA
Ionis treatment for Alexander disease granted orphan drug status from EMA
Read more →IONSIonis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Read more →IONSIonis licenses investigational Alzheimer's therapy
Ionis licenses investigational Alzheimer's therapy
Read more →IONSIonis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
Read more →IONSIonis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024
Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024
Read more →IONSIonis provides third quarter financial results and improved 2019 guidance
Ionis provides third quarter financial results and improved 2019 guidance
Read more →IONSIonis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Read more →IONSIonis licenses hepatitis B program to GSK
Ionis licenses hepatitis B program to GSK
Read more →IONSIonis Reports Second Quarter 2019 Financial Results
Ionis Reports Second Quarter 2019 Financial Results
Read more →IONSIonis announces appointment of Joan E. Herman to its board of directors
Ionis announces appointment of Joan E. Herman to its board of directors
Read more →IONSIonis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
Read more →IONSIonis announces appointment of Brett P. Monia Ph.D. to its board of directors
Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
Read more →IONSIonis Exceeds 2018 Financial Guidance
Ionis Exceeds 2018 Financial Guidance
Read more →IONSFirst Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
Read more →IONSIonis Announces Plans for Management Transitions in 2020
Ionis Announces Plans for Management Transitions in 2020
Read more →IONSIonis Reports Third Quarter 2018 Financial Results
Ionis Reports Third Quarter 2018 Financial Results
Read more →IONSIonis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Read more →IONSIonis Announces the Appointment of Two New Board Members
Ionis Announces the Appointment of Two New Board Members
Read more →IONSIONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington's Disease
IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington's Disease
Read more →IONSNew England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Read more →IONSIonis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
Read more →IONSIonis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases
Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases
Read more →IONSIONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
Read more →IONSIonis Reports Fourth Quarter and Full Year 2017 Financial Results
Ionis Reports Fourth Quarter and Full Year 2017 Financial Results
Read more →IONSIonis Licences New Antisense Drug for Kidney Disease to AstraZeneca
Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca
Read more →IONSIonis' Inotersen NDA Accepted for Priority Review by the FDA
Ionis' Inotersen NDA Accepted for Priority Review by the FDA
Read more →IONSIonis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
Read more →IONSIonis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
Read more →IONSIonis Announces Management Transitions
Ionis Announces Management Transitions
Read more →IONSIonis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA
Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA
Read more →IONSIonis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
Read more →IONSIonis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
Read more →IONSIonis to Independently Advance Inotersen and IONIS-FB-L Rx
Ionis to Independently Advance Inotersen and IONIS-FB-L Rx
Read more →IONSSPINRAZA (nusinersen) Approved in the European Union
SPINRAZA (nusinersen) Approved in the European Union
Read more →IONSIonis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Read more →IONSAkcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
Read more →IONSAkcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Read more →IONSIonis' 2016 Financial Results Outperform Financial Guidance
Ionis' 2016 Financial Results Outperform Financial Guidance
Read more →IONSIonis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
Read more →IONSIonis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Read more →IONSIonis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
Read more →IONSSPINRAZA (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
SPINRAZA (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Read more →IONSIonis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
Read more →IONSIonis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
Read more →IONSIonis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016
Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016
Read more →IONSAkcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease
Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease
Read more →IONSIonis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
Read more →IONSIonis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen
Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen
Read more →IONSIonis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities
Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities
Read more →IONSIonis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Read more →IONSIonis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
Read more →IONSIonis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
Read more →IONSIonis Pharmaceuticals and Kastle Therapeutics Announce Acquisition of KYNAMRO
Ionis Pharmaceuticals and Kastle Therapeutics Announce Acquisition of KYNAMRO
Read more →IONSIonis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise
Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise
Read more →IONSIonis' 2015 Financial Results Outperform Projections
Ionis' 2015 Financial Results Outperform Projections
Read more →IONSIonis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Read more →IONSIonis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Read more →IONSIonis Pharmaceuticals Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Ionis Pharmaceuticals Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Read more →IONSIsis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
Read more →IONSIsis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
Read more →IONSIsis Reports Financial Results and Highlights for Third Quarter 2015
Isis Reports Financial Results and Highlights for Third Quarter 2015
Read more →IONSIsis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies
Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies
Read more →IONSIsis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance
Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance
Read more →IONSPositive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Read more →IONSPositive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
Read more →IONSIsis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
Read more →IONSAkcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
Read more →IONSISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index
ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index
Read more →IONSIsis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy
Isis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy
Read more →IONSIsis Reports Financial Results and Highlights for First Quarter 2015
Isis Reports Financial Results and Highlights for First Quarter 2015
Read more →IONSIsis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Read more →IONSIsis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3 Rx
Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3 Rx
Read more →IONSIsis Reports Financial Results and Highlights for 2014
Isis Reports Financial Results and Highlights for 2014
Read more →IONSISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
Read more →IONSIsis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Read more →IONSIsis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
Read more →IONSISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
Read more →IONSIsis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Read more →IONSAstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
Read more →IONSIsis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
Read more →IONSIsis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
Read more →IONSIsis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
Read more →IONSIsis Reports Financial Results and Highlights for Second Quarter 2014
Isis Reports Financial Results and Highlights for Second Quarter 2014
Read more →IONSIsis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Read more →IONSIsis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes
Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes
Read more →IONSIsis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
Read more →IONSIsis Reports Updated Results from ISIS-SMN Rx Clinical Studies in Infants and Children with Spinal Muscular Atrophy
Isis Reports Updated Results from ISIS-SMN Rx Clinical Studies in Infants and Children with Spinal Muscular Atrophy
Read more →IONSIsis Reports Financial Results And Highlights For 2013
Isis Reports Financial Results And Highlights For 2013
Read more →IONSIsis Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx
Isis Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx
Read more →IONSJoseph Loscalzo, M.D., Ph.D., Joins Isis Pharmaceuticals' Board of Directors
Joseph Loscalzo, M.D., Ph.D., Joins Isis Pharmaceuticals' Board of Directors
Read more →IONSIsis Pharmaceuticals to Receive $7.5 Million from Alnylam
Isis Pharmaceuticals to Receive $7.5 Million from Alnylam
Read more →IONSIsis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Read more →IONSIsis Reports Financial Results and Highlights for Third Quarter 2013
Isis Reports Financial Results and Highlights for Third Quarter 2013
Read more →IONSIsis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
Read more →IONSIsis Reports Financial Results and Highlights for Second Quarter 2013
Isis Reports Financial Results and Highlights for Second Quarter 2013
Read more →IONSIsis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
Read more →IONSIsis Pharmaceuticals Prices Public Offering Of Common Stock
Isis Pharmaceuticals Prices Public Offering Of Common Stock
Read more →IONSIsis Reports Financial Results and Highlights for First Quarter 2013
Isis Reports Financial Results and Highlights for First Quarter 2013
Read more →IONSIsis Reports Financial Results and Highlights for 2012
Isis Reports Financial Results and Highlights for 2012
Read more →IONSIsis Initiates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Isis Initiates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Read more →IONSIsis Pharmaceuticals To Provide Update On FDA Approval Of KYNAMRO (mipomersen)
Isis Pharmaceuticals To Provide Update On FDA Approval Of KYNAMRO (mipomersen)
Read more →IONSIsis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Read more →IONSIsis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Read more →IONSBiogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
Read more →IONSIsis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
Read more →IONSIsis Reports Financial Results and Highlights for Third Quarter 2012
Isis Reports Financial Results and Highlights for Third Quarter 2012
Read more →IONSIsis Investment In Regulus Valued At $28 Million At Completion Of Regulus Initial Public Offering
Isis Investment In Regulus Valued At $28 Million At Completion Of Regulus Initial Public Offering
Read more →IONSIsis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
Read more →IONSIsis Reports Financial Results and Highlights for Second Quarter 2012
Isis Reports Financial Results and Highlights for Second Quarter 2012
Read more →IONSIsis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
Read more →IONSIsis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
Read more →IONSIsis Reports Financial Results and Highlights for 2011
Isis Reports Financial Results and Highlights for 2011
Read more →IONSISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Read more →IONSIsis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
Read more →IONSIsis Updates KYNAMRO Submission Timeline
Isis Updates KYNAMRO Submission Timeline
Read more →IONSIsis Adds Three New Drugs to Its Development Pipeline
Isis Adds Three New Drugs to Its Development Pipeline
Read more →IONSIsis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Read more →IONSIsis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIRx Produces Significant Reductions in apoC-III Protein Levels and Triglycerides
Isis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIRx Produces Significant Reductions in apoC-III Protein Levels and Triglycerides
Read more →IONSIsis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals
Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals
Read more →IONSIsis Reports Financial Results and Highlights for Third Quarter 2011
Isis Reports Financial Results and Highlights for Third Quarter 2011
Read more →IONSIsis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
Read more →IONSIsis Reports Financial Results and Highlights for Second Quarter 2011
Isis Reports Financial Results and Highlights for Second Quarter 2011
Read more →IONSIsis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Read more →IONSIsis Reports Financial Results and Highlights for 2010
Isis Reports Financial Results and Highlights for 2010
Read more →IONSIsis Initiates Phase 1 Clinical Trial of ISIS-FXIRx to Treat Clotting Disorders
Isis Initiates Phase 1 Clinical Trial of ISIS-FXIRx to Treat Clotting Disorders
Read more →IONSIsis Pharmaceuticals to Discuss Productive Regulatory Discussions Regarding the Mipomersen NDA Filing
Isis Pharmaceuticals to Discuss Productive Regulatory Discussions Regarding the Mipomersen NDA Filing
Read more →IONSIsis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Read more →IONSIsis and Xenon Collaborate to Develop Antisense Drugs Against Hemojuvelin and Hepcidin
Isis and Xenon Collaborate to Develop Antisense Drugs Against Hemojuvelin and Hepcidin
Read more →IONSIsis Reports Financial Results and Highlights for Third Quarter 2010
Isis Reports Financial Results and Highlights for Third Quarter 2010
Read more →IONSIsis Improves Financial Guidance and Reports Financial Results and Highlights for Second Quarter 2010
Isis Improves Financial Guidance and Reports Financial Results and Highlights for Second Quarter 2010
Read more →IONSIsis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
Read more →IONSISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
Read more →Competitive Position
How IONS ranks across every disease it competes inCompetitive Position is a premium feature
See how IONS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial